Abstract 160P
Background
Nano-liposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard treatment for advanced pancreatic cancer after gemcitabine-based chemotherapy. However, there are limited clinical data on its efficacy and safety. We therefore initiated the NAPOLEON-2 study. Imajima et al. have reported the final results of the retrospective portion of the study (ASCO GI, 2023). Here, we report on the pre-planned interim analysis of the prospective portion, focusing on safety.
Methods
This study is an ongoing multicenter observational study that took place in June 2021, with a target number of 150 cases. The primary endpoint was overall survival, with secondary endpoints including response rate, disease control rate, progression-free survival, dose intensity, and adverse events (AEs). According to the protocol regulation, an interim analysis was conducted once reaching half the number of target cases to verify the validity of further enrollment.
Results
The median follow-up period was 5.3 months. The median age was 71 years (range, 45–83), and the study included seven locally advanced cancer cases. Liver (43), peritoneum (28), and lung (21) were the most common metastatic sites. NFF was administered as a 2nd/3rd/4th- or later-line therapy to 44/25/6 cases, respectively. All patients had previously received gemcitabine-based therapy. For the initial dose, nano-liposomal irinotecan (NAL-IRI) or fluorouracil (FU) was reduced in 41 and 26 cases, respectively, mainly because of organ function (17%) and age (15%). Grade 3/4 hematological or non-hematological AEs occurred in 24 and 29 cases, respectively. Frequently observed grade 3/4 AEs were neutropenia (26%) and anorexia (16%). The median relative dose intensity was 71.5% for NAL-IRI and 82.9% for FU. Dose reduction during treatment was observed in 35 cases with NAL-IRI and 34 cases with FU, mainly from neutropenia (19%) and anorexia (13%).
Conclusions
These results reproduced the retrospective portion in the safety of NFF, validating this interim analysis. NFF was safely administered in practical clinical settings, so we determined that enrollment should be continued.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract
238P - Enfortumab-vedotin for metastatic urothelial carcinoma refractory to platinum-based chemotherapy and immune checkpoint inhibitors: A single institution experience
Presenter: Yuki Endo
Session: Poster Display
Resources:
Abstract